American Journal of Respiratory and Critical Care Medicine · 2020 · 42 citations · 48 references
Veterinary MedicineImmunologyInfectious DiseasesClinical ImmunologyImmunology Of Infectious DiseasesMucosal ImmunologyRespiratory DiseaseRespiratory Disease Epidemiology In ChildrenRespiratory Infectious DiseasesViral EpidemiologyAsymptomatic Infection EpidemiologyAsymptomatic Infection PrevalenceCommon ColdMixed-effects Logistic RegressionNeutralizing Antibody PrevalenceNeutralizing Antibody ResponsesPcr-based DetectionRhinovirus Infection
Abstract Rationale Rhinovirus (RV) C can cause asymptomatic infection and respiratory illnesses ranging from the common cold to severe wheezing. Objectives To identify how age and other individual-level factors are associated with susceptibility to RV-C illnesses. Methods Longitudinal data from the COAST (Childhood Origins of Asthma) birth cohort study were analyzed to determine relationships between age and RV-C infections. Neutralizing antibodies specific for RV-A and RV-C (three types each) were determined using a novel PCR-based assay. Data were pooled from 14 study cohorts in the United States, Finland, and Australia, and mixed-effects logistic regression was used to identify factors related to the proportion of RV-C versus RV-A detection. Measurements and Main Results In COAST, RV-A and RV-C infections were similarly common in infancy, whereas RV-C was detected much less often than RV-A during both respiratory illnesses and scheduled surveillance visits (P < 0.001, χ2) in older children. The prevalence of neutralizing antibodies to RV-A or RV-C types was low (5–27%) at the age of 2 years, but by the age of 16 years, RV-C seropositivity was more prevalent (78% vs. 18% for RV-A; P < 0.0001). In the pooled analysis, the RV-C to RV-A detection ratio during illnesses was significantly related to age (P < 0.0001), CDHR3 genotype (P < 0.05), and wheezing illnesses (P < 0.05). Furthermore, certain RV types (e.g., C2, C11, A78, and A12) were consistently more virulent and prevalent over time. Conclusions Knowledge of prevalent RV types, antibody responses, and populations at risk based on age and genetics may guide the development of vaccines or other novel therapies against this important respiratory pathogen.
48
Yury A. Bochkov, Kelly Watters, Shamaila Ashraf et al. · Proceedings of the National Academy of Sciences · 2015 · 428 citations · Full text
Association between human rhinovirus C and severity of acute asthma in children
J. Bizzintino, W-M. Lee, Ingrid A. Laing et al. · European Respiratory Journal · 2010 · 380 citations · Full text